Skip to main content
新芝生物 logo

新芝生物 — Investor Relations & Filings

Ticker · 920685 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 390 across all filing types
Latest filing 2025-04-20 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920685

About 新芝生物

https://www.scientz.com/

Scientz Biotechnology specializes in the design and manufacture of high-performance life science instruments and laboratory equipment. The product range features ultrasonic cell disruptors, freeze dryers, gene guns, and high-pressure homogenizers, which are essential for sample preparation, cell lysis, and genetic engineering. The company also provides specialized solutions for tissue grinding, ultrasonic cleaning, and precise temperature control. These instruments serve a broad spectrum of applications in molecular biology, pharmaceutical research, environmental science, and agricultural technology. By integrating advanced ultrasonic and cryogenic technologies, Scientz supports research institutions and industrial laboratories in achieving accurate and reproducible results across various scientific disciplines.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于宁波新芝生物科技股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 90% confidence The document is a sponsor’s verification opinion (“核查意见”) from Citic Securities regarding Ningbo New Zhi Biotechnology’s proposed use of idle IPO proceeds for cash management. It is not an annual or interim financial report, earnings release, dividend notice, board change, proxy, or M&A filing. Rather, it constitutes a regulatory compliance disclosure under the listing rules (a continuous disclosure or sponsor’s statement). Therefore it falls under the catch-all Regulatory Filings category (RNS).
2025-04-20 Chinese
2024年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Plan Announcement" for the year 2024 by Ningbo New Zhi Biotechnology Co., Ltd. It discusses the proposed dividend distribution plan based on the audited 2024 annual report, including details on the dividend per share, total dividend amount, and the approval process involving the board of directors, supervisory board, and the upcoming shareholders' meeting. The document also elaborates on the company's dividend policy, conditions for cash dividends, and the procedures for approval and implementation. It is an announcement of a dividend distribution plan rather than the actual dividend payment notice or the full annual report. The document length is 4428 characters, which is relatively short and mainly serves as a formal announcement of the dividend plan to shareholders and the market. Therefore, it fits best under the category of "Notice of Dividend Amount" (DIV), which covers announcements of dividend amounts, payment dates, and related shareholder details.
2025-04-20 Chinese
2024年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (立信会计师事务所) for the 2024 annual audit of 宁波新芝生物科技股份有限公司. It details the auditor's qualifications, audit process, quality control, and independence, but does not contain the actual audited financial statements or financial results. The document is a standalone audit performance evaluation report related to the audit of the 2024 annual report, not the annual report itself. It fits the definition of an Audit Report / Information (AR) as it focuses on audit firm performance and audit quality assessment rather than the full annual report or financial statements. The document length is 3802 characters, which is relatively short but contains substantive audit evaluation content, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2024
2025-04-20 Chinese
第八届董事会第十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 18th meeting of the 8th Board of Directors of Ningbo New Zhi Biotechnology Co., Ltd. It includes information about meeting attendance, agenda items, and voting results. The document references multiple reports and announcements (e.g., 2024 Annual Report, Audit Report, Independent Directors' Reports) that are disclosed separately on the Beijing Stock Exchange information platform. The document itself does not contain the full reports or financial statements but summarizes the board's decisions and approvals, indicating that these items will be or have been submitted to the shareholders or disclosed elsewhere. This type of document is a Board/Management Information announcement, specifically about board meeting resolutions and management reports, rather than the reports themselves or their publication announcements. Therefore, the correct classification is MANG (Board/Management Information). The document length (6186 characters) and content support this classification with high confidence.
2025-04-20 Chinese
募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金存放与实际使用情况的专项报告" which translates to a "Special Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised, their usage, management, and balance as of December 31, 2024. It includes detailed tables of fund usage, cash management, and investment projects. The document references regulatory approvals and audit verification reports related to the raised funds. It is a comprehensive report focused on the use and management of capital raised through a public stock issuance. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and the use of those funds. The document is over 10,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2025-04-20 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Ningbo Xinzhi Biotechnology Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It includes specifics about authorized cash management, types of financial products used, amounts, expected yields, risk controls, and internal approvals. The document references board and shareholder meeting resolutions approving the cash management plan. It is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is a regulatory announcement about the company's capital management activities related to raised funds. This fits best under Capital/Financing Update (CAP) as it updates on the company's use of raised capital for cash management purposes.
2025-04-06 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.